Puma Biotechnology (PBYI) Financials: Revenue & Earnings

PBYI price $10.55 -0.36 -3.34%

Ticker
PBYI
Price
$10.55
Change
-0.36 -3.34%
Market cap ?
$544.85M
P/E ?
20.15
Forward P/E ?
27.78
Dividend yield ?
0.00%
Beta ?
1.21
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
45
Value
52
Quality
75
Growth
9

Stocklytics score rationale: value 52, quality 75, growth 9.

Financials

2016201720182019202020212022202320242025
027700000251000000272260000225110000253155000228031000235637000230468000228371000

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast…

Fair value

PBYI fair value $10.85. Price $10.55. Price is about fair value.

Below fair value, but more expensive than usual. A smaller discount than on 85% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Average free cash flow, last three years 31.65M. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 10.95% (beta 1.2). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 51.62M. Net debt -1.09M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare PBYI

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-05—0.09—57.50M
2026-08-060.190.0456.50M53.00M
2026-05-07-0.04-0.1344.80M42.00M
2026-02-260.290.2459.90M68.62M
2025-11-060.210.0951.90M51.00M
2025-08-070.150.1149.20M52.00M
2025-05-080.100.0243.10M44.55M
2025-02-270.430.1059.10M52.51M
2024-11-070.410.3580.50M70.65M
2024-08-01-0.05-0.1044.40M44.70M
2024-05-02-0.05-0.2243.80M41.05M
2024-02-290.260.3072.20M73.55M
2023-11-020.120.0856.10M57.95M
2023-08-030.050.0154.60M51.73M
2023-05-040.03-0.0752.80M49.63M
2023-03-02-0.120.0665.70M57.06M
2022-11-03-0.01-0.0757.10M50.47M
2022-08-040.210.0259.50M52.62M
2022-05-05-0.08-0.1745.70M45.07M
2022-03-030.10-0.0955.40M47.17M
2021-11-04-1.09-0.3146.24M55.06M
2021-08-05-0.13-0.2753.38M53.00M
2021-05-060.400.0998.17M69.96M
2021-02-25-0.38-0.3152.56M53.00M
2020-11-05-0.79-0.3950.75M36.69M
2020-08-060.08-0.3070.58M264.68M
2020-05-07-0.43-0.7751.22M91.71M
2020-02-20-0.29-0.4862.92M104.15M
2019-11-06-0.44-0.7156.40M90.93M
2019-08-08-0.97-0.9553.92M52.81M
2019-05-09-0.26-0.6899.10M259.10M
2019-02-28-0.80-0.7771.10M68.41M
2018-11-01-0.37-0.9762.60M164.19M
2018-08-09-1.17-1.2650.77M54.67M
2018-05-09-0.65-0.7566.52M102.33M
2018-03-01-1.71-1.9821.60M24.89M
2017-11-09-2.07-2.756.08M7.57M
2017-08-09-2.10-2.10——
2017-05-10-1.97-1.98——
2017-03-01-2.04-2.02——

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-14WILSON TROY EDWARDSell5.00K$9.1045.50K
2026-09-14Cesano AlessandraBuy50.00K$2.93146.50K
2026-09-14Cesano AlessandraSell62.15K$9.12566.99K
2026-09-14Cesano AlessandraSell50.00K$2.93146.50K
2026-07-06AUERBACH ALAN HSell44.06K$8.26364.05K
2026-07-06HUNT DOUGLAS MSell8.46K$8.2669.90K
2026-07-06NOUGUES MAXIMO FSell9.39K$8.2677.56K
2026-06-12WILSON TROY EDWARDSell10.80K$7.2077.75K
2026-06-12Stuglik Brian MSell8.10K$7.2058.31K
2026-06-12Senderowicz AdrianSell27.00K$7.20194.31K
2026-06-12MOYES JAY MSell22.00K$7.22158.80K
2026-06-12Dorval AllisonSell11.61K$7.2083.58K
2026-06-11WILSON TROY EDWARDBuy27.00K——
2026-06-11Stuglik Brian MBuy27.00K——
2026-06-11Senderowicz AdrianBuy27.00K$7.20194.31K
2026-06-11MILLER MICHAEL PATRICKBuy27.00K——
2026-06-11MOYES JAY MBuy27.00K——
2026-06-11Dorval AllisonBuy27.00K——
2026-06-11Cesano AlessandraBuy27.00K——
2026-02-18AUERBACH ALAN HBuy159.78K——
2026-02-18AUERBACH ALAN HBuy227.47K$6.681.52M
2026-02-18HUNT DOUGLAS MBuy49.39K——
2026-02-18HUNT DOUGLAS MBuy70.32K$6.68469.74K
2026-02-18NOUGUES MAXIMO FBuy46.74K——
2026-02-18NOUGUES MAXIMO FBuy66.54K$6.68444.49K
2026-01-07AUERBACH ALAN HSell18.01K$5.88105.89K
2026-01-07HUNT DOUGLAS MSell5.01K$5.8829.48K
2026-01-07NOUGUES MAXIMO FSell6.41K$5.8837.65K
2026-01-06AUERBACH ALAN HSell16.94K$5.8498.99K
2026-01-06HUNT DOUGLAS MSell3.97K$5.8423.22K
2026-01-06NOUGUES MAXIMO FSell4.54K$5.8426.53K
2025-11-11MILLER MICHAEL PATRICKSell20.00K$4.8697.23K
2025-07-18Cesano AlessandraSell27.00K$3.3790.91K
2025-07-09NOUGUES MAXIMO FSell3.94K$3.5413.91K
2025-07-09HUNT DOUGLAS MSell3.44K$3.5412.17K
2025-07-09AUERBACH ALAN HSell21.58K$3.5476.29K
2025-07-08NOUGUES MAXIMO FSell5.59K$3.5319.74K
2025-07-08HUNT DOUGLAS MSell4.37K$3.5315.45K
2025-07-08AUERBACH ALAN HSell25.59K$3.5390.42K
2025-06-13WILSON TROY EDWARDSell10.80K$3.4036.72K
2025-06-13Stuglik Brian MSell8.10K$3.3927.46K
2025-06-13Senderowicz AdrianSell27.00K$3.4091.80K
2025-06-13MOYES JAY MSell22.00K$3.4074.80K
2025-06-13Dorval AllisonSell11.61K$3.4039.47K
2025-06-13Cesano AlessandraSell12.15K$3.4041.31K
2025-06-11MILLER MICHAEL PATRICKBuy27.00K——
2025-06-11Senderowicz AdrianBuy27.00K——
2025-06-11MOYES JAY MBuy27.00K——
2025-06-11Dorval AllisonBuy27.00K——
2025-06-11Stuglik Brian MBuy27.00K——
2025-06-11WILSON TROY EDWARDBuy27.00K——
2025-06-11Cesano AlessandraBuy27.00K——
2025-02-07NOUGUES MAXIMO FBuy61.46K——
2025-02-07NOUGUES MAXIMO FBuy85.07K$2.78236.49K
2025-02-07Ludwig Jeffrey JeromeBuy47.84K——
2025-02-07Ludwig Jeffrey JeromeBuy66.22K$2.78184.09K
2025-02-07HUNT DOUGLAS MBuy48.12K——
2025-02-07HUNT DOUGLAS MBuy66.60K$2.78185.16K
2025-02-07AUERBACH ALAN HBuy198.40K——
2025-02-07AUERBACH ALAN HBuy274.62K$2.78763.45K
2025-01-02NOUGUES MAXIMO FSell10.23K$3.1532.23K
2025-01-02Ludwig Jeffrey JeromeSell9.44K$3.1529.74K
2025-01-02HUNT DOUGLAS MSell8.63K$3.1527.21K
2025-01-02AUERBACH ALAN HSell33.84K$3.15106.66K
2024-08-12MILLER MICHAEL PATRICKSell23.36K$3.4981.47K
2024-07-17NOUGUES MAXIMO FSell4.16K$3.7015.38K
2024-07-17Ludwig Jeffrey JeromeSell2.60K$3.709.62K
2024-07-17HUNT DOUGLAS MSell3.64K$3.7013.46K
2024-07-17AUERBACH ALAN HSell21.92K$3.7081.13K
2024-07-02NOUGUES MAXIMO FSell5.29K$3.2717.31K
2024-07-02Ludwig Jeffrey JeromeSell6.05K$3.2719.78K
2024-07-02HUNT DOUGLAS MSell4.35K$3.2714.21K
2024-07-02AUERBACH ALAN HSell18.89K$3.2761.73K
2024-06-18WILSON TROY EDWARDBuy27.00K——
2024-06-18Stuglik Brian MBuy27.00K——
2024-06-18Senderowicz AdrianBuy27.00K——
2024-06-18MILLER MICHAEL PATRICKBuy27.00K——
2024-06-18MOYES JAY MBuy27.00K——
2024-06-18Dorval AllisonBuy27.00K——
2024-06-18Cesano AlessandraBuy27.00K——
2024-06-13WILSON TROY EDWARDSell27.00K$3.3389.90K
2024-06-13Stuglik Brian MSell9.90K$3.3933.53K
2024-06-13Senderowicz AdrianSell27.00K$3.3389.82K
2024-06-13MOYES JAY MSell22.00K$3.3473.47K
2024-06-13Dorval AllisonSell11.00K$3.3737.10K
2024-03-15AUERBACH ALAN HBuy6.58K——
2024-03-15AUERBACH ALAN HBuy9.05K$5.0045.23K
2024-02-12Wong Alvin FBuy43.31K——
2024-02-12Wong Alvin FBuy59.95K$6.36381.26K
2024-02-12NOUGUES MAXIMO FBuy43.31K——
2024-02-12NOUGUES MAXIMO FBuy59.95K$6.36381.26K
2024-02-12Ludwig Jeffrey JeromeBuy27.07K——
2024-02-12Ludwig Jeffrey JeromeBuy37.47K$6.36238.28K
2024-02-12AUERBACH ALAN HBuy160.80K——
2024-02-12AUERBACH ALAN HBuy222.57K$6.361.42M
2024-02-12HUNT DOUGLAS MBuy37.89K——
2024-02-12HUNT DOUGLAS MBuy52.45K$6.36333.59K
2024-01-03Wong Alvin FSell7.73K$4.4934.69K
2024-01-03Ludwig Jeffrey JeromeSell12.96K$4.4958.12K
2024-01-03AUERBACH ALAN HSell41.40K$4.49185.70K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 166, holders +7 vs prior quarter. Ownership 76.19%.

HolderSharesChangeChange %Value
ACORN CAPITAL ADVISORS, LLC4.13M00.00%33.50M
BLACKROCK, INC.3.80M205.78K+5.72%30.86M
AMERICAN CENTURY COMPANIES INC2.32M403.65K+21.06%18.82M
ACADIAN ASSET MANAGEMENT LLC2.05M11.76K+0.58%16.65M
RENAISSANCE TECHNOLOGIES LLC1.84M-106.20K-5.47%14.89M
VANGUARD CAPITAL MANAGEMENT LLC1.84M17.96K+0.99%14.89M
VANGUARD PORTFOLIO MANAGEMENT LLC1.83M90.95K+5.24%14.81M
LSV ASSET MANAGEMENT1.62M435.11K+36.78%13.12M
DIMENSIONAL FUND ADVISORS LP1.52M81.91K+5.70%12.31M
GEODE CAPITAL MANAGEMENT, LLC1.34M322.06K+31.66%10.86M
O'SHAUGHNESSY ASSET MANAGEMENT, LLC1.12M-14.39K-1.26%9.11M
STATE STREET CORP952.16K34.58K+3.77%7.72M
KENNEDY CAPITAL MANAGEMENT LLC873.25K-16.35K-1.84%7.08M
BRIDGEWAY CAPITAL MANAGEMENT, LLC791.62K16.27K+2.10%6.42M
RITHOLTZ WEALTH MANAGEMENT749.80K-24.51K-3.17%6.08M
AQR CAPITAL MANAGEMENT LLC725.19K-75.00K-9.37%5.88M
GOLDMAN SACHS GROUP INC669.16K-563-0.08%5.43M
NORTHERN TRUST CORP652.39K10.63K+1.66%5.29M
CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD.642.95K-139.85K-17.87%5.21M
UBS GROUP AG636.76K102.53K+19.19%5.16M
MILLENNIUM MANAGEMENT LLC602.24K-875.28K-59.24%4.88M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP532.45K-5.71K-1.06%4.32M
SEI INVESTMENTS CO418.67K-89.51K-17.61%3.40M
GLOBEFLEX CAPITAL L P382.81K33.16K+9.48%3.10M
BANK OF NEW YORK MELLON CORP360.73K12.85K+3.69%2.93M

Earnings and financials

Puma Biotechnology, Inc. (PBYI) trades at $10.55, with a market cap of $544.85M and a trailing P/E of 20.15. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
027700000251000000272260000225110000253155000228031000235637000230468000228371000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Puma Biotechnology (PBYI) Financials: Revenue & Earnings

PBYI$10.55-0.36 -3.34%

$544.85M

Market Cap

20.15

P/E

27.78

Forward P/E

45

Score

Price History